Skip to main content
. 2020 Oct 27;4(20):5322–5335. doi: 10.1182/bloodadvances.2020002042

Figure 5.

Figure 5.

Patients with AML stratified based on high and low CODEG22 score. (A-B) OS and EFS of patients including all cytogenetic abnormalities from the GSE6891 (A) and the GSE10358 (B) data sets. (C-D) OS and EFS of patients with CA-AML from the GSE6891 (C) and GSE10358 (D) data sets. (E) OS and EFS of patients with CN-AML from the GSE10358 data set. (F) OS of all patients from CN-AML cohorts 1 and 2 available in the GSE12417 data set. (G) OS, EFS, and RFS of all patients from the ALFA-0701 cohort. (H) OS and EFS of patients with AML from the retrospective real-time qPCR (qRT-PCR) FILO cohort (n = 142). CODEG22 scores above and below the median in each cohort are labeled high (in red) and low score (in blue), respectively. A log-rank test was used to compare the survival curves of the high and low score subsets.